Clinical Trial: A Phase 1b Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07020117) titled 'A Phase 1b Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors' on May 28.

Brief Summary: This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Part 2 dose.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Urothelial Carcinoma Bladder Triple Negative Breast Cancer (TNBC) Hormone Receptor Positive Breast Adenocarcinoma Non Small Ce...